Georgios Bontzos1, Saghar Bagheri2, Larissa Ioanidi3, Ivana Kim2, Ioannis Datseris4, Evangelos Gragoudas2, Stamatina Kabanarou5, Joan Miller2, Miltiadis Tsilimbaris3, Demetrios G Vavvas6. 1. Department of Ophthalmology, University of Crete, Heraklion, Greece; Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Korgialenio Benakio General Hospital, Athens, Greece. 2. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts. 3. Department of Ophthalmology, University of Crete, Heraklion, Greece. 4. OMMA Eye Institute, Athens, Greece. 5. Korgialenio Benakio General Hospital, Athens, Greece. 6. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts. Electronic address: vavvas@meei.harvard.edu.
Abstract
PURPOSE: To investigate the inter-individual variability in duration of anti-vascular endothelial growth factor (VEGF) treatment effect in neovascular age-related macular degeneration (nvAMD). DESIGN: Prospective observational multi-centered study. PARTICIPANTS: Forty-eight patients with nvAMD treated with anti-VEGF injections were included. Both treatment naive (n=25) as well as patients who had previously received treatment with ranibizumab (n=23) more than one month prior to their enrollment were recruited. METHODS: Patients received injection with ranibizumab (0.5 mg/0.05 ml) and were followed weekly for 4 weeks with spectral-domain OCT (SD-OCT) assessing the time to maximal reduction of central retinal thickness (CRT) and the presence of intraretinal and subretinal fluid. Other data collected included age, gender, visual acuity, axial length, lens status, and previous injections. The Shapiro-Wilk test was used to examine normal distributions for all variables. Correlations were examined by calculating Spearman's correlation coeficient. Distributions of quantitative variables are described as means (±SD). Qualitative variables are summarized by counts and percentage. MAIN OUTCOME MEASURES: Time to maximal reduction of CRT and intra- and subretinal fluid after ranibizumab injection. RESULTS: A total of 48 eyes of 48 patients (age 74.8±8.3 years, 62.5% female, 52% treatment naive, 35.4% pseudophakic) were assessed. Two-thirds (64.6%) reached maximal CRT reduction earlier than the standard 4-week interval: 6.3% at 1 week postinjection, 22.9% at 2 weeks postinjection, and 35.4% at 3 weeks postinjection. Only 35.4% of patients had maximal CRT reduction at 4 weeks. Twenty percent of treatment-naive and 34.8% of non-naive patients had a week-4 CRT that was >35 μm thicker than the earlier occuring lowest CRT value (nadir). The time to maximal CRT reduction was not related to axial length, age, lens status, or history of injections. CONCLUSIONS: Optimal dosing interval for maximal CRT reduction may be less than 4 weeks for a significant proportion of patients. Most patients will be classified as complete responders if intervals less than 4 weeks are used to assess anti-VEGF treatment response. Disease load rather than eye size appears to be the driver of anti-VEGF treatment duration and therefore, dosing interval needs to be optimized in the cohort of short-term responders.
PURPOSE: To investigate the inter-individual variability in duration of anti-vascular endothelial growth factor (VEGF) treatment effect in neovascular age-related macular degeneration (nvAMD). DESIGN: Prospective observational multi-centered study. PARTICIPANTS: Forty-eight patients with nvAMD treated with anti-VEGF injections were included. Both treatment naive (n=25) as well as patients who had previously received treatment with ranibizumab (n=23) more than one month prior to their enrollment were recruited. METHODS:Patients received injection with ranibizumab (0.5 mg/0.05 ml) and were followed weekly for 4 weeks with spectral-domain OCT (SD-OCT) assessing the time to maximal reduction of central retinal thickness (CRT) and the presence of intraretinal and subretinal fluid. Other data collected included age, gender, visual acuity, axial length, lens status, and previous injections. The Shapiro-Wilk test was used to examine normal distributions for all variables. Correlations were examined by calculating Spearman's correlation coeficient. Distributions of quantitative variables are described as means (±SD). Qualitative variables are summarized by counts and percentage. MAIN OUTCOME MEASURES: Time to maximal reduction of CRT and intra- and subretinal fluid after ranibizumab injection. RESULTS: A total of 48 eyes of 48 patients (age 74.8±8.3 years, 62.5% female, 52% treatment naive, 35.4% pseudophakic) were assessed. Two-thirds (64.6%) reached maximal CRT reduction earlier than the standard 4-week interval: 6.3% at 1 week postinjection, 22.9% at 2 weeks postinjection, and 35.4% at 3 weeks postinjection. Only 35.4% of patients had maximal CRT reduction at 4 weeks. Twenty percent of treatment-naive and 34.8% of non-naive patients had a week-4 CRT that was >35 μm thicker than the earlier occuring lowest CRT value (nadir). The time to maximal CRT reduction was not related to axial length, age, lens status, or history of injections. CONCLUSIONS: Optimal dosing interval for maximal CRT reduction may be less than 4 weeks for a significant proportion of patients. Most patients will be classified as complete responders if intervals less than 4 weeks are used to assess anti-VEGF treatment response. Disease load rather than eye size appears to be the driver of anti-VEGF treatment duration and therefore, dosing interval needs to be optimized in the cohort of short-term responders.
Authors: Barbara Kloeckener-Gruissem; Daniel Barthelmes; Stephan Labs; Christian Schindler; Malaika Kurz-Levin; Stephan Michels; Johannes Fleischhauer; Wolfgang Berger; Florian Sutter; Moreno Menghini Journal: Invest Ophthalmol Vis Sci Date: 2011-07-01 Impact factor: 4.799
Authors: Hrvoje Bogunovic; Sebastian M Waldstein; Thomas Schlegl; Georg Langs; Amir Sadeghipour; Xuhui Liu; Bianca S Gerendas; Aaron Osborne; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2017-06-01 Impact factor: 4.799
Authors: Michael W Stewart; Philip J Rosenfeld; Fernando M Penha; Fenghua Wang; Zohar Yehoshua; Elena Bueno-Lopez; Pedro F Lopez Journal: Retina Date: 2012-03 Impact factor: 4.256
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Julie L Gasperini; Amani A Fawzi; Ani Khondkaryan; Linda Lam; Lawrence P Chong; Dean Eliott; Alexander C Walsh; John Hwang; SriniVas R Sadda Journal: Br J Ophthalmol Date: 2011-07-26 Impact factor: 4.638
Authors: W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang Journal: Eye (Lond) Date: 2015-04-17 Impact factor: 3.775
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: Brandon G Busbee; Allen C Ho; David M Brown; Jeffrey S Heier; Ivan J Suñer; Zhengrong Li; Roman G Rubio; Phillip Lai Journal: Ophthalmology Date: 2013-01-23 Impact factor: 12.079
Authors: Issahy Cano; Zhengping Hu; Dina B AbuSamra; Magali Saint-Geniez; Yin Shan Eric Ng; Pablo Argüeso; Patricia A D'Amore Journal: Front Cell Dev Biol Date: 2021-09-20
Authors: Bjørn K Fabian-Jessing; Thomas Stax Jakobsen; Emilie Grarup Jensen; Sidsel Alsing; Silja Hansen; Lars Aagaard; Anne Louise Askou; Toke Bek; Thomas J Corydon Journal: Invest Ophthalmol Vis Sci Date: 2022-08-02 Impact factor: 4.925